NCT04386252View on ClinicalTrials.gov

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

January 31, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

AV-COVID-19

Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein

Sponsors
All Listed Sponsors
lead

Aivita Biomedical, Inc.

INDUSTRY

NCT04386252 - Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults | Biotech Hunter | Biotech Hunter